title: Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
abstract: The toxicity and therapeutic efficacy of escalating doses of anti-carcinoembryonic antigen x anti-N alpha-(diethylenetriamine-N,N,N',N''-tetraacetic acid)-In bispecific monoclonal antibody (F6-734) and iodine 131-labeled bivalent hapten were determined in a Phase I/II trial. A total of 26 patients with recurrences of medullary thyroid cancer documented by imaging and a rise in serum thyrocalcitonin were enrolled. Twenty to 50 mg of F6-734 and 40-100 mCi of 131I-hapten were injected 4 days apart. Quantitative scintigraphy was performed after the second injection for dosimetry estimations in eight cases. Clinical, biological, and morphological follow-up was carried out for 1 year after treatment. The mean percentage of injected activity per gram of tumor at the time of maximum uptake was 0.08% (range, 0.003-0.26%). The tumor biological half-life ranged from 3 to 95 days, and tumor doses ranged from 2.91 to 184 cGy/mCi. The estimated tumor-to-nontumor dose ratios were 43.8 x 53.4, 29.6 x 35.3, 10.9 x 13.6, and 8.4 x 10.0 for total body, red marrow, liver, and kidney, respectively. Grade III/IV hematological toxicity was observed in seven patients, most of them with bone metastases. Among the 17 evaluable patients, 4 pain reliefs, 5 minor tumor responses, and 4 biological responses with decrease of thyrocalcitonin were observed. Nine patients developed human anti-mouse antibody. Dose-limiting toxicity was hematological, and maximum tolerated activity was 48 mCi/m2 in this group of patients, most of whom had suspected bone marrow involvement. The therapeutic responses observed in patients mainly with a small tumor burden are encouraging for the performance of a Phase II trial with minimal residual disease.
authors.affiliation: Nuclear Medicine Department, René Gauducheau Cancer Center, Nantes, France.
authors.forename: F
authors.initials: F
authors.lastname: Kraeber-Bodéré
authors.forename: S
authors.initials: S
authors.lastname: Bardet
authors.forename: C A
authors.initials: CA
authors.lastname: Hoefnagel
authors.forename: M R
authors.initials: MR
authors.lastname: Vieira
authors.forename: J P
authors.initials: JP
authors.lastname: Vuillez
authors.forename: A
authors.initials: A
authors.lastname: Murat
authors.forename: T C
authors.initials: TC
authors.lastname: Ferreira
authors.forename: M
authors.initials: M
authors.lastname: Bardiès
authors.forename: L
authors.initials: L
authors.lastname: Ferrer
authors.forename: I
authors.initials: I
authors.lastname: Resche
authors.forename: E
authors.initials: E
authors.lastname: Gautherot
authors.forename: E
authors.initials: E
authors.lastname: Rouvier
authors.forename: J
authors.initials: J
authors.lastname: Barbet
authors.forename: J F
authors.initials: JF
authors.lastname: Chatal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D018033:Antibodies, Bispecific / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018276:Carcinoma, Medullary / Q000532:radiotherapy*; D005260:Female; D006241:Haptens / Q000627:therapeutic use*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D013964:Thyroid Neoplasms / Q000532:radiotherapy*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018033:Antibodies, Bispecific; D006241:Haptens; D007457:Iodine Radioisotopes